Humana Inc. to Post FY2022 Earnings of $24.68 Per Share, Jefferies Financial Group Forecasts (NYSE:HUM)

Humana Inc. (NYSE:HUM – Get Rating) – Equities researchers at Jefferies Financial Group boosted their FY2022 earnings estimates for shares of Humana in a research report issued on Wednesday, April 27th. Jefferies Financial Group analyst D. Windley now forecasts that the insurance provider will earn $24.68 per share for the year, up from their prior estimate of $24.32. Jefferies Financial Group also issued estimates for Humana’s FY2023 earnings at $27.80 EPS.

Several other equities analysts have also weighed in on the company. Zacks Investment Research upgraded Humana from a “sell” rating to a “hold” rating and set a $445.00 target price on the stock in a report on Friday, February 4th. SVB Leerink dropped their price objective on Humana from $528.00 to $525.00 and set an “outperform” rating on the stock in a research note on Thursday, February 3rd. StockNews.com upgraded Humana from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 20th. Truist Financial lifted their price objective on Humana from $460.00 to $490.00 in a research note on Thursday, April 7th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Humana from $418.00 to $435.00 in a research note on Thursday, February 3rd. Seven research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $486.28.

NYSE HUM opened at $444.56 on Monday. Humana has a fifty-two week low of $351.20 and a fifty-two week high of $475.44. The stock’s 50-day moving average is $440.69 and its two-hundred day moving average is $435.26. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.53 and a quick ratio of 1.62. The firm has a market cap of $56.34 billion, a P/E ratio of 18.86, a price-to-earnings-growth ratio of 1.37 and a beta of 0.94.

Humana (NYSE:HUM – Get Rating) last posted its earnings results on Wednesday, April 27th. The insurance provider reported $8.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $6.79 by $1.25. Humana had a return on equity of 17.27% and a net margin of 3.51%. The company had revenue of $23.97 billion for the quarter, compared to analyst estimates of $23.54 billion. During the same period last year, the company earned $7.67 earnings per share. The business’s revenue was up 16.0% compared to the same quarter last year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Thursday, June 30th will be given a dividend of $0.7875 per share. This represents a $3.15 annualized dividend and a dividend yield of 0.71%. The ex-dividend date of this dividend is Wednesday, June 29th. Humana’s payout ratio is 13.36%.

Institutional investors have recently modified their holdings of the business. Spire Wealth Management bought a new stake in shares of Humana in the 4th quarter valued at $30,000. Bell Investment Advisors Inc acquired a new position in Humana in the 3rd quarter worth $26,000. BerganKDV Wealth Management LLC boosted its stake in Humana by 885.7% in the 4th quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 62 shares during the period. Riverview Trust Co acquired a new position in Humana in the 1st quarter worth $32,000. Finally, Selective Wealth Management Inc. acquired a new position in Humana in the 4th quarter worth $35,000. Institutional investors own 92.96% of the company’s stock.

Humana Company Profile (Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading